Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Vertex Pharmaceuticals Incorporated”

980 pharma patents match "Vertex Pharmaceuticals Incorporated" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 980
Index total 30,257
Page 5 / 41

Quick answer

This filtered view shows 980 pharmaceutical patents matching "Vertex Pharmaceuticals Incorporated" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

980 results for “Vertex Pharmaceuticals Incorporated” · 30,257 patents in full index Clear search

  1. US 11186566

    Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  2. US 11179367

    Pharmaceutical compositions for treating cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  3. US 11179394

    Method for treating cancer using a combination of Chk1 and ATR inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  4. US 11155533

    Crystalline forms and compositions of CFTR modulators

    Vertex Pharmaceuticals Incorporated · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  5. US 11147770

    Pharmaceutical composition and administrations thereof

    Vertex Pharmaceuticals Incorporated · Granted Oct 19, 2021 · Expires Oct 14, 2041

    granted
  6. US 11124805

    Methods, compositions and kits for increasing genome editing efficiency

    Vertex Pharmaceuticals Incorporated · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  7. US 11117900

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  8. US 11110108

    Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted
  9. US 11110086

    Compounds useful as inhibitors of ATR kinase and combination therapies thereof

    Vertex Pharmaceuticals Incorporated · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted
  10. US 11084804

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Aug 10, 2021 · Expires Aug 5, 2041

    granted
  11. US 11066417

    Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

    Vertex Pharmaceuticals Incorporated · Granted Jul 20, 2021 · Expires Jul 15, 2041

    granted
  12. US 11059826

    Pteridinone compounds and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  13. US 11052075

    Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof

    Vertex Pharmaceuticals Incorporated · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  14. US 11021465

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  15. US 11008305

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted May 18, 2021 · Expires May 13, 2041

    granted
  16. US 10988477

    GCN2 inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Apr 27, 2021 · Expires Apr 22, 2041

    granted
  17. US 10987348

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Apr 27, 2021 · Expires Apr 22, 2041

    granted
  18. US 10980746

    Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

    Vertex Pharmaceuticals Incorporated · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  19. US 10975061

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  20. US 10973830

    Substituted quinoxaline DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  21. US 10961232

    Substituted pyrazines as ATR kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted
  22. US 10913761

    2,7-dibromospiro[fluorene-9,4′-piperidine] compounds

    Vertex Pharmaceuticals Incorporated · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  23. US 10906891

    Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

    Vertex Pharmaceuticals Incorporated · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  24. US 10874673

    Inhibitors of influenza viruses replication

    Vertex Pharmaceuticals Incorporated · Granted Dec 29, 2020 · Expires Dec 24, 2040

    granted